Company / Operating Cash Flow
Denali Therapeutics Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$412.6M
FY2025
5-year range
-$412.6M / $416.2M
FY2021-FY2025
Trend
-18.7%
vs FY2024
Sector context
#205 of 216
Health Care
What the data says
Among 216 Health Care companies, Denali Therapeutics Inc. is in the bottom 5% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$413M in FY2025 to $416M in FY2022.
Based on SEC 10-K filings.
-$413M in FY2025.
Declined from -$358M to -$413M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 216This company -$412.6M Sector average $659.0M
▼
-162.6% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 18.7% year-over-year.
- Ranks #205 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$412.6M | -18.7% |
| FY2024 | -$347.7M | +2.9% |
| FY2023 | -$358.0M | -186.0% |
| FY2022 | $416.2M | +374.6% |
| FY2021 | -$151.6M | -402.5% |
| FY2020 | $50.1M | +165.4% |
| FY2019 | -$76.6M | -6.6% |
| FY2018 | -$71.9M | +6.2% |
| FY2017 | -$76.6M | -6.6% |
| FY2016 | -$71.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026